Onkologie. 2013:7(3):140-143

Vemurafenib in the target therapy of metastatic melanoma

Ivo Kocák, Ilona Kocáková, Stanislav ©pelda
Klinika komplexní onkologické péče, MOÚ a LF MU, Brno

Metastatic melanoma is an aggressive disease. Historical treatment options have been limited (e.g. dacarbazine, temozolomide, high dose

interleukin-2) and associated with poor outcomes. Vemurafenib is a first-in-class, small molecule BRAFV600 inhibitor. Vemurafenib is approved

in the EU as monotherapy in adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma. In the trial BRIM-2 a BRIM-3

vemurafenib significantly improved both overall survival (OS) and progression free survival (PFS) in patients with unresectable melanoma.

Keywords: metastatic melanoma, dacarbazine, vemurafenib, BRAFV600 mutation, BRIM-2, BRIM-3

Published: July 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kocák I, Kocáková I, ©pelda S. Vemurafenib in the target therapy of metastatic melanoma. Onkologie. 2013;7(3):140-143.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Keatting M. Vemurafenib in unresectable or metastatic melanoma, Biodrugs 2012; 26(5): 325-334. Go to original source... Go to PubMed...
    2. Finn L, Markovic SN, Joseph RW. Therapy for metastatic melanoma: the past, present, and future. BMC Med 2012; 10: 23. Go to original source... Go to PubMed...
    3. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 Aug 26; 363(9): 809-819. Go to original source... Go to PubMed...
    4. European Medicines Agency. Zelboraf (vemurafenib) 240 mg film-coatd tablets: EU summary of product charakteristics (online).
    5. Kim, et al. Significant Long-Term Survival Benefit Demonstrated With Vemurafenib in Ongoing Phase I Study. Society for Melanoma Research - 9th International Melanoma Congress, SMR 2012.
    6. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366(8): 707-14. Go to original source... Go to PubMed...
    7. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364(26): 2507-2516. Go to original source... Go to PubMed...
    8. Chapman PB, Hauschild A, Robert C, et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicentre trial comparing BRAF inhibitor vemurafenib with dacarbazina in previously untreated patients with BRAFV600E-mutated melanoma (abstract no. 8502 plus oral presentation). 48th ASCO; 2012 Jun 1-5; Chicago. Go to original source...
    9. Menzies, et al. Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clin Can Res 2012; 18: 3242. Go to original source... Go to PubMed...
    10. McArthur GA, et al. Efficacy of vemurafenib in BRAFV600K mutation-positive melanoma disease - results from the Phase 3 clinical study BRIM3. Society for Melanoma Research - 9th International Melanoma Congress |SMR 2012.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.